Navigation Links
Reportlinker Adds Future Directions in Regenerative Medicine
Date:5/26/2011

tial partners or investment opportunities.

Research and analysis highlights

The first regenerative cell therapies to generate significant market value (within the next five years) will be based on allogeneic adult cells, and will target tissues that are naturally sheltered from patients' immune systems.

Autologous cells are not rejected by the patient's immune system, so are potentially safer than allogeneic cells and more suitable for permanent tissue replacement. "High tech" therapies based on reprogrammed autologous cells (e.g. induced pluripotent stem cells) may still be 20 years from market.

Tissue engineering still faces technical hurdles, including vascularization of grafted tissue and safe breakdown of scaffold materials. Research and regulatory efforts must be coordinated internationally to develop a stronger "evidence base" for regenerative medicine that is accessible and acceptable to all stakeholders.

Key reasons to purchase this research

• What is regenerative medicine and why are so many companies and investors excited about it?

• Which companies are currently developing new regenerative treatments and what approaches are they pursuing?

• What partnerships have been formed to develop new therapies, and where are the opportunities for further deals?

• What will the next generation of regenerative medicine candidates look like, and which indications will they treat?

• What hurdles do these candidates face en route to the marketplace?

TABLE OF CONTENTS

About the author 2

Disclaimer 2

Executive Summary 12

An introduction to regenerative medicine 12

Allogeneic regenerative cell therapies 12

Autologous regenerative cell therapies 13

Tissue engineering 14

Regenerative drug molecules 14

Regenerative devices and implants 15

The future of regenerative medicin
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
2. Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries
3. Reportlinker Adds Analytical Tool - Lymphoma
4. Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope
5. Reportlinker Adds Industrial Biotechnology China News 1104
6. Reportlinker Adds Healthcare Information Technology
7. Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
8. Reportlinker Adds Global Biomaterial Market (2010 - 2015)
9. Reportlinker Adds Genetics Reports Bundle
10. Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Biomarkers: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... call "hostile-environment technology." These are the machines, devices and ... are dangerous or impossible for humans to tread. Like ... reactor facilities. Two Arizona State University electrical engineers ... generation of these technologies, supported by a recent $1.7 ...
... BRNO, Czech Republic, November 16, 2011 ... provides complete diagnostics, treatment, and preventive care in ... MMCI is the only health care provider in ... the OECI (Organisation of European Cancer Institutes). ...
... Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company ... today announced top-line data from its recently completed ... pharmacodynamics (PD), safety and tolerability of subcutaneous bolus ... chronic heart failure. Nile is developing cenderitide as ...
Cached Biology Technology:Arizona State University engineers aim to improve performance of technology in extreme environments 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 3Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 2Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 3Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 4
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... analysis has found that many doctors report that they ... and testing services to their female patients. Published early ... the American Cancer Society, the study indicates that efforts ... and discourage them for average-risk women. Women with ...
... association study published in the August issue of ... that can predict which patients with Hodgkin,s lymphoma are ... treatment. Knowing in advance who is at risk could ... patients who are most susceptible to long-term damage. ...
... target for nitric oxide has been revealed in studies of how ... cause of food-poisoning. "Nitric oxide is naturally produced ... body to ward off infection," explained the senior author of the ... professor of laboratory medicine, microbiology and medicine. Nitric oxide ...
Cached Biology News:Mismatch between cancer genetics counseling and testing guidelines and physician practices 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 3New target found for nitric oxide's attack on salmonella bacteria 2New target found for nitric oxide's attack on salmonella bacteria 3
... Chicken polyclonal to LYZL6 ( Abpromise ... Antigen: Synthetic peptide: ... HVDCQD , corresponding to amino acids ... Entrez Gene ID: 57151 ...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Mouse Anti-Lamin B...
Biology Products: